If you live in NSW, read more about RSV prevention, symptoms and treatment in the respiratory syncytial virus (RSV) fact sheet.
NSW Health RSV (respiratory syncytial virus) vulnerable babies program will be implemented in a phased approach that offers Beyfortus™ (nirsevimab) to the most vulnerable babies from March 2024 to September 2024.
Parents and carers can find information on Beyfortus™ (nirsevimab) on the information for parents and carers webpage.
Parents and carers of Aboriginal babies can find information on Beyfortus™ (nirsevimab) on the information for parents and carers of Aboriginal babies webpage.
RSV is a common respiratory infection. It mostly affects young children. Adults can also get it. RSV symptoms are usually mild. However, some children and adults can get very sick and need to go to hospital for treatment.
Case presentations are usually highest in late autumn or winter. Some babies and older people can get an immunisation or RSV vaccine. Read information about the NSW Health RSV (respiratory syncytial virus) vulnerable babies program below.
Read the latest statement on nirsevimab from the Australian Technical Advisory Group on Immunisation (ATAGI).
ATAGI has also released the latest statement regarding Arexvy, a RSV vaccine registered for use in adults aged 60 years and older.
Infants who are vulnerable to severe illness from RSV are eligible for a free monoclonal antibody Beyfortus™ (nirsevimab) immunisation. RSV monoclonal antibodies are a passive immunisation that provides antibodies directly to the infant so they have immediate protection against RSV. The trade name of nirsevimab is Beyfortus™.
Beyfortus™ (nirsevimab) will be initially offered to hospitalised infants in 2024 who meet the following eligibility criteria:
**at clinician’s judgement in consultation with specialist paediatric infectious diseases physician, specialist in paediatric immunisation, or designated Beyfortus™ (nirsevimab) program lead at a NSW Health facility. This group will include a variety of children with conditions/disorders requiring continuous home oxygen/respiratory support including neurological conditions, congenital malformations of the upper and/or lower airways, chronic suppurative lung diseases including cystic fibrosis with severe respiratory function impairment.
The NSW Health RSV vulnerable babies program commenced on 25 March 2024. It will run from March 2024 to September 2024. There is limited global availability of Beyfortus™ (nirsevimab). This means the NSW program will be rolled out in two phases. The targeted cohorts in each phase are:
All private health facilities that administer Beyfortus™ (nirsevimab) to eligible infants are required to provide a weekly report to NSW Health on every Friday between April 2024 and September 2024.
Private health facilities should complete the reporting template and submit to NSW Health at moh-vaccreports@health.nsw.gov.au via the relevant Secure File Transfer management system every Friday between April 2024 and September 2024.
For more information, refer to:
Synagis (palivizumab) is also a monoclonal antibody used to protect against RSV infections in Australia. Synagis (palivizumab) is only offered to children who are at the highest risk of severe illness from RSV. It is given as a course of up to five injections at one-month intervals throughout the RSV season.